Cross-source identity
National Provider Identifier 1154448991 as it appears in every federal dataset Fonteum holds. Each row is a distinct public source; the chip carries the source and the snapshot date behind that field — the record-level form of the source-provenanced graph.
| Federal source | Key | What it provides | Provenance |
|---|
| CMS NPPES | NPI 1154448991 | Registry identity — psychiatrist, taxonomy 2084P0800X | Source:CMS NPPESSnapshot 2026-05-06 |
| CMS Open Payments | NPI 1154448991 | 215 industry-payment records, 2024 | Source:CMS Open PaymentsSnapshot PY2024 |
| CMS Medicare Part D | NPI 1154448991 | 42 drugs prescribed, 2024 | Source:CMS Part DSnapshot DY2024 |
| Fonteum entity graph | entity f021ec50… | Canonical resolved node · 2 identifier(s) · 4 edge(s) | Source:Entity graphSnapshot 2026-06-11 |
Industry payments
Payments and transfers of value this clinician received from drug and device manufacturers, disclosed under the Physician Payments Sunshine Act. A payment is a disclosure, not a judgment.
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $65,647 | 29 |
| Consulting Fee | $51,263 | 22 |
| Honoraria | $9,750 | 4 |
| Travel and Lodging | $7,611 | 32 |
| Compensation for serving as faculty or as a speaker for a medical education program |
| Manufacturer | Amount | Records |
|---|---|---|
| Axsome Therapeutics, Inc. | $46,284 | 36 |
| Supernus Pharmaceuticals, Inc. | $30,601 | 66 |
| Neurocrine Biosciences, Inc. | $20,196 |
Prescribing
Prescriptions written under Medicare Part D, aggregated by drug across the program. Totals reflect claims paid, not patients treated.
| Drug | Claims | Drug cost |
|---|---|---|
| Austedo Xr(Deutetrabenazine) | 14 | $169,763 |
| Austedo(Deutetrabenazine) | 13 | $92,679 |
| Rexulti(Brexpiprazole) | 18 | $38,780 |
| Wellbutrin Xl(Bupropion Hcl) | 14 | $33,415 |
| Trintellix(Vortioxetine Hydrobromide) | 15 | $16,067 |
Beneficiary counts below 11 are suppressed by CMS — the total shown is a lower bound.
Quality
CMS Quality Payment Program Merit-based Incentive Payment System (MIPS) final score, where this clinician participated. Absence of a score is not a quality signal — many clinicians report through a group or are exempt.
Enrollment & sanctions
Screening aid — re-confirm any match against the issuing list before acting. A clean result means no record was found in the federal OIG LEIE or the state Medicaid lists Fonteum currently holds (NY, OH, GA), not a guarantee that none exists elsewhere. Not a legal or credentialing certification.
Ownership & affiliations
One-hop relationships in the resolved entity graph — chain membership, ownership, and operation edges, each backed by a federal source row. Most individual clinicians carry none; edges populate for owners and organizations as the Lane D backfill runs.
| Relationship | Entity | Source |
|---|---|---|
| ← pays | Neos Therapeutics, Lp (CO) | cms_open_payments |
| ← pays | Noven Pharmaceuticals, Inc. (FL) | cms_open_payments |
| ← pays | Noven Therapeutics, Llc (FL) | cms_open_payments |
| ← pays | Corium, Llc (MA) | cms_open_payments |
| $7,219 |
| 3 |
| 20 |
| Teva Pharmaceuticals Usa, Inc. | $17,644 | 20 |
| Alkermes, Inc. | $13,565 | 16 |